Brief: Guard Therapeutics’ Application For Phase 2 Clinical Trial Approved In Germany

Disruptive Pharma AB (publ)

06/01/2022 06:25

Jan 6 (Reuters) - Guard Therapeutics International Ab (Publ)
 GUARD.ST :
    * GUARD THERAPEUTICS SAID ON WEDNESDAY IT'S APPLICATION TO
CONDUCT
PHASE 2 CLINICAL TRIAL OF ROSGARD IS APPROVED BY GERMAN
MEDICINES REGULATOR
    * STUDY IS PLANNED TO START IN Q1 OF 2022 AND GERMAN STUDY
CENTRES
ARE EXPECTED TO RECRUIT SIGNIFICANT PROPORTION OF TOTAL NUMBER
OF PATIENTS
    * COMPANY AWAITS ETHICAL APPROVAL OF STUDY AS LAST STEP IN
THE
GERMAN CLINICAL TRIAL APPLICATION PROCEDURE BEFORE STUDY CAN
START

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN5ztH51
 Further company coverage:  GUARD.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))